Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Expanding Treatment Options for Bleeds Related to Oral Anticoagulants

December 20, 2017 By Law Offices of Thomas J. Lamb, P.A.

UPDATE:  The FDA announced that it will push back its decision on whether to approve the reversal agent AndexXa to May 4, 2018.  The original review date was set for February 3, 2018, but the FDA wanted to consider additional information it had requested from Portola, the drug's manufacturer. (12/28/17).   Risk of Bleeding … [Read more...]

Filed Under: Unsafe Drugs Tagged With: ACC, American College of Cardiology, andexxa, antidotes, apixaban, bleeding reversal agents, dabigatran, direct oral anticoagulants, DOACs, edoxaban, Eliquis, FDA, major bleeding events, oral anticoagulants side effects, Pradaxa, Praxbind, rivaroxaban, Savaysa, Xarelto

Warfarin vs. Eliquis, Pradaxa, Xarelto, and Savaysa: Which is Better?

November 9, 2016 By Law Offices of Thomas J. Lamb, P.A.

There in an ongoing debate amongst medical professionals concerning the effectiveness and safety of warfarin in comparison to the non–vitamin K antagonist oral anticoagulants (NOACs)--such as Eliquis, Xarelto, Savaysa, and Pradaxa--for patients with atrial fibrillation. According to the Healio Cardiology today article, "Merits of warfarin, newer … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, drug injury, drug side effects, Eliquis, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, intracranial hemorrhages, NOACs, Pradaxa, reversal agents, safety warnings, Savaysa, warfarin, Xarelto

What’s in a Name? Debate on What to Call Novel Oral Anticoagulants

September 30, 2016 By Law Offices of Thomas J. Lamb, P.A.

Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis.  The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]

Filed Under: Unsafe Drugs Tagged With: anticoagulants, antidotes, bleeding events, blood thinners, DOAC, drug injury, Eliquis, FDA, Gastrointestinal (GI) Bleeds, hemorrhagic strokes, heparin, increased risks, intracranial hemorrhages, NOAC, ODI, Pradaxa, reversal agents, safety warnings, Savaysa, side effects, SODA, TSOAC, warfarin, Xarelto

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.